KCG Holdings Inc. boosted its position in PDL BioPharma, Inc. (NASDAQ:PDLI) by 42.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 72,147 shares of the biotechnology company’s stock after buying an additional 21,382 shares during the period. KCG Holdings Inc.’s holdings in PDL BioPharma were worth $164,000 as of its most recent filing with the SEC.
Other hedge funds have also recently modified their holdings of the company. FMR LLC increased its stake in shares of PDL BioPharma by 14.3% in the fourth quarter. FMR LLC now owns 934,050 shares of the biotechnology company’s stock worth $1,980,000 after buying an additional 116,700 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of PDL BioPharma by 15.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,282,180 shares of the biotechnology company’s stock worth $9,078,000 after buying an additional 582,265 shares during the period. HPM Partners LLC purchased a new stake in shares of PDL BioPharma during the first quarter worth $163,000. Seizert Capital Partners LLC purchased a new stake in shares of PDL BioPharma during the first quarter worth $2,706,000. Finally, Norges Bank purchased a new stake in shares of PDL BioPharma during the fourth quarter worth $5,068,000. 87.72% of the stock is owned by institutional investors.
PDL BioPharma, Inc. (PDLI) opened at 2.72 on Friday. PDL BioPharma, Inc. has a 52-week low of $1.93 and a 52-week high of $3.77. The firm has a market capitalization of $419.10 million, a PE ratio of 6.25 and a beta of 0.58. The company’s 50-day moving average is $2.47 and its 200-day moving average is $2.30.
PDL BioPharma (NASDAQ:PDLI) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported $0.26 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.09 by $0.17. The firm had revenue of $143.80 million during the quarter, compared to analyst estimates of $56.30 million. PDL BioPharma had a net margin of 23.03% and a return on equity of 9.07%. The business’s quarterly revenue was up 584.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.09 EPS. Analysts forecast that PDL BioPharma, Inc. will post $0.61 EPS for the current fiscal year.
WARNING: This story was first posted by BNB Daily and is the sole property of of BNB Daily. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/pdl-biopharma-inc-pdli-position-raised-by-kcg-holdings-inc-updated.html.
A number of analysts have recently weighed in on PDLI shares. Zacks Investment Research raised shares of PDL BioPharma from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Wednesday. ValuEngine raised shares of PDL BioPharma from a “hold” rating to a “buy” rating in a report on Friday, August 4th. BidaskClub downgraded shares of PDL BioPharma from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Cowen and Company reiterated a “hold” rating on shares of PDL BioPharma in a research report on Wednesday, May 3rd. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $4.00 price objective on shares of PDL BioPharma in a research report on Thursday, August 10th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $3.50.
PDL BioPharma Company Profile
PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.
Receive News & Ratings for PDL BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.